Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: Evaluation of expression under immunomodulatory therapy

Acta Neurologica Scandinavica

Volumn 123, Issue 1, 2011, Pages 8-12

  Kurne, A ^a   Guc, D ^a   Canpinar, H ^a   Aydin, O F ^b   Sayat, G ^a   Yorubulut M ^c   Esendagli, G ^a   Karabudak, R ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c Primer Imaging Center   (Turkey)

Author keywords

B cell activating factor; Immunomodulation; Interferon 1 therapy; Multiple sclerosis; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

B CELL ACTIVATING FACTOR; BETA INTERFERON; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOMODULATION; LYMPHOCYTE; MALE; MULTIPLE SCLEROSIS; PARAMETER; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; B-CELL ACTIVATING FACTOR; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 78650044417     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01346.x     Document Type: Article

References (24)

1. Lünemann JD, Waiczies S, Ehrlich S et al.Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002;168:4881-8.
2. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9.
3. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;25:2572-81.
4. Pers JO, Devauchelle V, Daridon C et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome. Arthritis Rheum 2007;56:1464-77.
5. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, Van Den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003;18:1-6.
6. Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008;70:2252-60.
7. Aktas O, Prozorovski T, Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006;12:305-16.
8. Lum JJ, Pilon AA, Sanchez-Dardon J et al.Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol 2001;75:11128-36.
9. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol 2001;166:1314-9.
10. Aktas O, Smorodchenko A, Brocke S et al.Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005;46:421-32.
11. Krumbholz M, Faber H, Steinmeyer F et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455-63.
12. Thangarajh M, Kisiswa L, Pirskanen R, Hillert J. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand J Immunol 2007;65:461-6.
13. Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195-200.
14. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmström P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004;152:183-90.
15. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-9.
16. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 2007;190:170-6.
17. Rinta S, Kuusisto H, Raunio M et al.Apoptosis-related molecules in blood in multiple sclerosis. J Neuroimmunol 2008;205:135-41.
18. Hamzaoui K, Houman H, Hentati F, Hamzaoui A. BAFF is up-regulated in central nervous system of neuro-Behçet's disease. J Neuroimmunol 2008;200:111-4.
19. Mariette X, Roux S, Zhang J et al.The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 2003;62:168-71.
20. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-27.
21. Andersson PB, Waubant E, Goodkin DE. How should we proceed with disease-modifying treatments for multiple sclerosis? Lancet 1997;349:586-7.
22. Khademi M, Wallström E, Andersson M, Piehl F, Di Marco R, Olsson T. Reduction of both pro- and anti-inflammatory cytokines after 6-months of interferon beta-1a treatment of multiple sclerosis. J Neuroimmunol 2000;103:202-10.
23. Kilinc M, Saatci-Cekirge I, Karabudak R. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment. J Interferon Cytokine Res 2003;23:127-33.
24. Karabudak R, Kurne A, Guc D, Sengelen M, Canpinar H, Kansu E. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. J Neurol 2004;251:279-83.